Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Position Trimmed by Principal Financial Group Inc.

Principal Financial Group Inc. decreased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 13.2% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 244,766 shares of the biotechnology company's stock after selling 37,318 shares during the period. Principal Financial Group Inc. owned approximately 0.25% of Sarepta Therapeutics worth $15,621,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Peregrine Capital Management LLC raised its holdings in Sarepta Therapeutics by 28.0% in the first quarter. Peregrine Capital Management LLC now owns 68,874 shares of the biotechnology company's stock valued at $4,396,000 after buying an additional 15,070 shares during the period. New York State Teachers Retirement System raised its holdings in Sarepta Therapeutics by 3.3% in the first quarter. New York State Teachers Retirement System now owns 79,361 shares of the biotechnology company's stock valued at $5,065,000 after buying an additional 2,512 shares during the period. Sovran Advisors LLC raised its holdings in Sarepta Therapeutics by 112.9% in the first quarter. Sovran Advisors LLC now owns 57,509 shares of the biotechnology company's stock valued at $3,670,000 after buying an additional 30,494 shares during the period. Harbour Capital Advisors LLC purchased a new position in Sarepta Therapeutics in the first quarter valued at approximately $289,000. Finally, Sava Infond d.o.o. raised its holdings in Sarepta Therapeutics by 50.0% in the first quarter. Sava Infond d.o.o. now owns 4,500 shares of the biotechnology company's stock valued at $287,000 after buying an additional 1,500 shares during the period. Hedge funds and other institutional investors own 86.68% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on SRPT shares. JPMorgan Chase & Co. lowered their price objective on shares of Sarepta Therapeutics from $30.00 to $28.00 and set an "overweight" rating for the company in a research report on Thursday. Robert W. Baird lowered their price objective on shares of Sarepta Therapeutics from $60.00 to $30.00 and set an "outperform" rating for the company in a research report on Tuesday, June 17th. William Blair reaffirmed a "market perform" rating on shares of Sarepta Therapeutics in a research report on Friday, June 20th. Morgan Stanley reaffirmed an "equal weight" rating and issued a $40.00 price objective (down previously from $113.00) on shares of Sarepta Therapeutics in a research report on Monday, June 16th. Finally, Oppenheimer lowered their price objective on shares of Sarepta Therapeutics from $123.00 to $45.00 and set an "outperform" rating for the company in a research report on Friday, June 20th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, Sarepta Therapeutics has an average rating of "Hold" and an average price target of $58.54.

Sarepta Therapeutics Stock Performance

Sarepta Therapeutics stock traded down $0.90 during mid-day trading on Friday, reaching $18.17. The company's stock had a trading volume of 3,075,372 shares, compared to its average volume of 2,241,596. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of -6.75 and a beta of 0.45. The business has a 50 day moving average price of $30.98 and a 200-day moving average price of $71.91. The company has a current ratio of 4.02, a quick ratio of 2.46 and a debt-to-equity ratio of 1.00. Sarepta Therapeutics, Inc. has a twelve month low of $16.88 and a twelve month high of $154.13.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). The business had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The business's revenue for the quarter was up 80.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.73 EPS. Sell-side analysts predict that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.